GlaxoSmithKline
This article was originally published in The Tan Sheet
Executive Summary
U.S. Consumer Healthcare business considering expansion of Kennedy Twp., Penn. facilities near Pittsburgh or relocation. Firm says SmithKline Beecham/Glaxo Wellcome merger, subsequent Block Drug acquisition are driving need for more office space. GSK previously said it would close three former Block manufacturing sites in Puerto Rico, UK, Ireland over next two years and incorporate operations into GSK facilities (1"The Tan Sheet" June 25, In Brief)
You may also be interested in...
GlaxoSmithKline
Firm is proposing to close three former Block Drug consumer health care product manufacturing sites in Puerto Rico, UK, Ireland over next two years. Operations at these sites are duplicated elsewhere in GSK's network, company says, and can be incorporated into GSK facilities in UK, U.S. Three sites manufacture dental products such as Sensodyne, Poli-Grip, Polident and other smaller brands. GSK completed its purchase of Block in January (1"The Tan Sheet" Jan. 22, In Brief). Block's products eventually will bear GSK name
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands